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Abstract
Background: High-dose (HD) chemotherapy with melphalan and autologous blood stem cell transplantation (ABSCT)
for treatment of symptomatic multiple myeloma (MM) on an outpatient basis has been well established in the USA
and Canada, whereas in Germany and Western Europe an inpatient setting is the current standard. We report on a
German single-centre program to offer the procedure on an outpatient basis to selected patients.
Methods: Major requirements included: patients had to have family and/or other caregivers, had to be able to reach
the hospital within 45 min and have an ECOG performance score of 0–1. Patients with severe co-morbidities were not
included.
Results: From September 2012 until April 2016, 21 patients with MM stage IIIA were enrolled. All engrafted within the
expected time range (median 14 days), and no severe adverse events occurred. 14 patients (67%) had an episode of
neutropenic fever and blood cultures were positive in 4 patients (19%). Although rather liberal criteria for hospital
admission were applied, 14 patients (67%) were treated entirely on an outpatient basis.
Conclusions: HD chemotherapy and ABSCT on an outpatient basis is safe and feasible if it is conducted in an elaborate
surveillance program. The feedback from patients was very positive, thus encouraging further expansion of the program.
Keywords: Multiple myeloma, Autologous blood stem cell transplantation, High-dose chemotherapy, Outpatient setting,
Outpatient supportive care
Background
High-dose (HD) chemotherapy and autologous blood
stem cell transplantation (ABSCT) is a standard of care in
transplant eligible patients with multiple myeloma (MM)
and a variety of malignant diseases [1–4]. Initially estab-
lished as a single ABSCT in newly diagnosed MM, subse-
quent trials have shown the benefit of a tandem ABSCT
in overall survival, particularly in those patients who do
not reach at least a very good partial remission after the
first autograft [5–8]. Moreover, HD chemotherapy and
ABSCT is also an effective treatment option for relapse
MM patients [9–11].
MM patients undergoing HD chemotherapy and
ABSCT have traditionally been admitted to the hospital
for several weeks. With the increasing ABSCT experience
of the transplanting centres, the patients’ wish for a shorter
stay in the hospital, increasing number of nosocomial in-
fections and growing economic pressure, particularly in
view of increasing absolute numbers of ABSCTs in Europe
during the last decade [12], there is a clear trend towards
outpatient treatment. The experience from performing
HD chemotherapy and ABSCT in an outpatient setting in
the late 1990s has indicated a high degree of safety, feasi-
bility, cost saving and patient satisfaction [13–16]. Al-
though it has been well established in the United States of
America [17–19] and Canada [20, 21], only single reports
on outpatient HD chemotherapy and ABSCT in Europe
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are available [22, 23]. To the best of our knowledge, the
outpatient treatment option has not been established as a
routine in a transplant centre in Germany so far.
Since 2012, we have performed HD chemotherapy and
ABSCT on an outpatient basis in individually selected MM
patients within an elaborated program. Currently, this out-
patient ABSCT program is being extended to a higher case
number, and up to 2 patients undergo this treatment in
parallel at a time. This report summarizes our experience
of 21 ABSCTs performed on an outpatient basis. The aim
of this retrospective study is to demonstrate our approach
and analyse the safety and efficacy of the program.
Methods
Study design and data collection
A retrospective single-centre analysis of MM patients
(n = 21) who underwent HD melphalan chemotherapy
and ABSCT as an outpatient between September 2012
and February 2016 at our University Hospital outpatient
clinic was performed. Clinical parameters (gender, age,
Eastern Cooperative Oncology Group (ECOG) score), dis-
ease stage at first diagnosis according to Salmon and
Durie, type of monoclonal protein, modality of induction
and mobilization therapy, peripheral blood stem cell
(PBSC) collection result, remission status pre and post
ABSCT, transplanted CD34+ cell number, haematological
reconstitution data, toxicities and supportive interventions
were assessed retrospectively.
To identify potential factors predicting the need for in-
patient admission and illustrate the possible differences
in toxicities and haematological reconstitution, patients
were retrospectively grouped according to the necessity
of hospital admission (hereafter referred to as “outpa-
tients” and “temporary inpatients”). Retrospective data
analysis was approved by the Ethics Committee of the
Medical Faculty, Heidelberg University. Patients’ in-
formed written consent was obtained.
Inclusion and exclusion criteria and safety issues
The following inclusion criteria were defined: general
transplantation eligibility, age 18–70 years, ECOG per-
formance status 0–1, implanted port catheter system or
excellent peripheral vein conditions, availability of an
accompanying care-taking person, availability by cell
phone, transport distance from home or hotel to the
outpatient clinic of ≤45 min, patient’s compliance with
the given instructions and patient’s informed consent.
The exclusion criteria were defined as follows: light-
chain amyloidosis, detection of antibodies to human
leukocyte antigens (HLA) and/or insufficient platelet
increase after platelet transfusion, insurmountable lan-
guage barrier, medical complications during induction or
mobilization therapy and severe comorbidities like cardiac
or renal insufficiency.
There was an intention to treat all of the patients on
an outpatient basis in our outpatient clinic. If indicated,
a hospital admission could be arranged instantly, and pa-
tients could contact a haematologist by phone at any
time. All of the patients received a detailed information
brochure regarding the prevention of infection, body care,
oral hygiene, diet and physical activity during aplasia.
HD chemotherapy and ABSCT
Indication and eligibility for HD melphalan and ABSCT
were determined by the treating physician. All of the
patients received HD melphalan (100 mg/m2, day -3 and
day -2, 1 h infusion) as the conditioning regimen. The
melphalan dosage was reduced by 50% due to comorbid-
ities in one patient with refractory myeloma who had
already undergone three previous courses of HD mel-
phalan chemotherapy and ABCST. A minimum of 2.0 ×
106 CD34+ cells/kg patient’s body weight was re-infused
in all cases on day 0 using standard supportive therapy
(500 mg acetaminophen p.o., 2 mg clemastine intraven-
ous (i.v.), and 10 mg dihydrocodeine p.o.). No growth
factors were used post-transplantation.
Monitoring and Supportive Care
Monitoring
During patient monitoring visits, clinical examination,
vital signs assessment (blood pressure, heart rate, body
temperature, weight) and laboratory testing (blood
count, electrolytes, creatinine, liver values, coagulation
status and C-reactive protein) were performed daily, in-
cluding weekends. All visits as well as any treatment
took place in the outpatient clinic in a specified area and
with staff previously introduced to the patients in order
to avoid any stay in the waiting area to reduce the risk of
infection. Daily visits were continued until recovery of leu-
cocytes >1.0 × 109/L, neutrophils >0.5 × 109/L and plate-
lets >50 × 109/L in the absence of any signs of infection.
Antiemetic prophylaxis
Compared to an antiemetic prophylaxis given in the
inpatient setting [24], an intensified oral supportive
medication for preventing chemotherapy-induced nausea
and vomiting was administered: dexamethasone 2 to
4 mg day -3 and dexamethasone 1 to 2 mg day -2 to day
-1, granisetron 2 mg days -3 to day +4, aprepitant
125 mg day -3, aprepitant 80 mg day -2 to day +2. Dimen-
hydrinate and/or metoclopramide p.o. were prescribed to
the patients as home medication, if required. Moreover,
pantoprazole 40 mg p.o. was administered once daily.
Hydration and prophylaxis of stomatitis
For all patients, 1 to 2 L of 0.9% saline solution and, de-
pending on the serum potassium level, 10–30 mval potas-
sium chloride were administered by i.v. daily. To prevent
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stomatitis, patients were strongly recommended to rinse
the mouth with Caphosol® (calcium-phosphate solution)
at least once per hour during their stay at the outpatient
clinic and at home.
Non-steroidal anti-rheumatics were avoided due to
unintended fever suppression, but opioid analgesics were
used for pain management, e.g. in case of stomatitis.
Antiviral and antibiotic prophylaxis and treatment
Patients received daily ciprofloxacin 2×500 mg per os
(p.o.) until haematological reconstitution and aciclovir
2×400 mg p.o. for 6 months after ABSCT. In case of
fever (>38.3 °C), an empirical antibiotic treatment with
1 g ertapenem i.v. per 24 h was initiated. Blood cultures
were obtained and further diagnostic tests including im-
aging techniques were performed if necessary. At the
discretion of the treating physician, the empirical i.v.
antibiotic therapy was initiated in some cases at subfeb-
rile temperatures when C-reactive protein (CRP) eleva-
tion was observed. In case of persisting fever >72 h,
antibiotic therapy was substituted by i.v. 3x piperacillin
4 g/tazobactam 0.5 g per 24 h, and the patient was ad-
mitted to the hospital. Intravenous antibiotic therapy
was continued until the fifth day without fever or haem-
atological reconstitution.
Criteria for inpatient admission and discharge
Rounds were conducted daily, and the patient’s clinical
status was evaluated by the treating physician. In align-
ment with previously published policies of other centres
[15], we pursued a rather liberal strategy for hospitalization
of outpatients, primarily based on clinical parameters.
Patients were admitted to the hospital in case of fever per-
sisting for more than 72 h. Further criteria for inpatient
admission were ECOG score >2, pneumonia, sepsis, un-
controlled pain, diarrhoea and an indication for parenteral
nutrition in case of grade 3 stomatitis or nausea and
vomiting. A discharge from hospital and further treat-
ment again as an outpatient was possible, depending
on the patient’s clinical status.
Assessment of haematological reconstitution and
remission status
After ABSCT, blood count was performed on a daily
basis until platelet and leucocyte/neutrophil engraft-
ment. Platelet engraftment was defined as the first of 3
consecutive days on which platelets reached 20 × 109/L
without platelet transfusion. Because the platelet count
did not fall below 20 × 109/L or a platelet transfusion
was necessary in some patients, we also assessed days
until platelets ≥50 × 109/L as a second variable for plate-
let engraftment. Leucocyte engraftment was defined by a
leucocyte count of ≥1.0 × 109/L. Days with leucocytes
<1.0 × 109/L were recorded as days in aplasia. Neutrophil
recovery was defined as the first of 3 days on which neu-
trophils reached 0.5 × 109/L. The remission status was
assessed according to international uniform response
criteria for MM [25].
Assessment of patient satisfaction
Patients’ satisfaction was assessed using a structured
questionnaire after hematologic reconstitution when
daily monitoring at the outpatient clinic was discontin-
ued. The patients were asked to give marks ranging from
1 (very good) to 6 (unsatisfactory) for the medical care
provided by physicians and nurses and for the treatment
at the outpatient clinic as a whole. They were also asked
to determine whether they would, if indicated, undergo
further HD chemotherapy and ABSCT in the outpatient
setting again.
Statistical Analysis
Descriptive statistics and comparison between groups
were performed using R studio 7.6. Data are given as ab-
solute numbers and percentage and, if not otherwise
stated, the median and range. For the comparison of cat-
egorical variables, Fisher’s Exact test in case of 2 × 2
contingency tables or its Freeman-Halton extension in
case of 2 × >2 contingency tables was used. To identify
differences among groups in case of continuous vari-
ables, a Wilcoxon-Mann-Whitney test was performed.
Leucocyte, neutrophil and platelet recovery over time
was calculated and plotted using Kaplan-Meier survival
analysis. To calculate the differences between the en-
graftment curves, a log-rank test was used. A P-value
<0.05 was considered statistically significant.
Results
Patients’ characteristics
Overall, 21 MM patients were identified as candidates
for an outpatient treatment, and HD chemotherapy and
ABSCT was initiated in our outpatient clinic. In 14 cases
(67%), therapy was performed completely on an out-
patient basis. In 7 patients (33%), hospital admission and
at least temporary inpatient treatment were indicated.
Patients were grouped according to the necessity of hos-
pital admission (“outpatients” vs. “temporary inpatients”).
More than twice as many male than female patients
(n = 15 vs. n = 6) were intended to be treated on an out-
patient basis. ECOG performance status prior to HD
chemotherapy and ABSCT was 0 in 20 (95%) and 1 in 1
(5%) patients. All patients had an available accompany-
ing person throughout the treatment period, except for
one patient who suddenly and unexpectedly no longer
had a care-giving family member available. Almost all of
the patients (n = 19, 90%) had a central port catheter sys-
tem. The majority of the patients had received bortezo-
mib, doxorubicin, dexamethasone (PAD) or bortezomib,
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cyclophosphamide, dexamethasone (VCD) as induction
therapy. Virtually all of the patients (n = 20, 95%) had re-
ceived cyclophosphamide, doxorubicin, dexamethasone
(CAD) for stem cell mobilization. A median PBSC stem
cell collection result of 9.7 (range 7.4–24.8) and 13.7
(range 9.1–23.0) CD34+ cells x106/kg was noted in out-
and inpatients, respectively. Further details are shown in
Table 1. No significant differences were found in the pa-
tients’ characteristics between outpatient and temporary
inpatient cases.
HD chemotherapy and ABSCT
The majority of patients received HD chemotherapy and
ABSCT as a first-line treatment (n = 15, 71%). 6 patients
(29%) received an autologous transplant as part of a sal-
vage therapy regimen. 3 patients underwent a second
course of HD chemotherapy and ABSCT in an outpatient
setting as consolidation therapy or in case of relapse after
3–28 months. The median age at ABSCT was 59 (51–70)
and 62 (51–67) years in out- and inpatients, respectively.
All of the patients received HD melphalan. In one case,
the melphalan dosage was reduced to 50% as an individual
decision in a heavily pretreated patient, as described
above. The remission status is summarized in Table 2.
Post-ABSCT treatment, toxicities and supportive care
The overall cumulative treatment duration for 21 pa-
tients was 444 days, of which 391 days (88%) were spent
on an outpatient basis and 53 days (12%) on an inpatient
basis. On average, the treatment duration was 21 (range
18–25) and 22 (range 19–31) days for out- and tempor-
ary inpatients, respectively. No significant differences in
treatment duration were found between the patient co-
horts (P = 0.38). Overall, 7 patients had an indication for
temporary hospital admission. 4 patients were admitted
to the hospital because of neutropenic fever persisting
more than 72 h (patient no. 5, 7, 18, 21). In 2 further
cases, hospital admission was indicated due to grade III
stomatitis (patient no. 1 and 16). In one case, inpatient
monitoring was initiated due to a local inflammation of
the port catheter implantation site (patient no. 13). Pa-
tients who were temporarily admitted to the hospital
spent a median of 15 (range 8–19) days as outpatients
and 5 (range 2–18) days as inpatients. The sequence of
days spent as an out- and inpatient during HD chemo-
therapy and ABSCT for each patient is indicated in Fig. 1.
In 3 cases, patients were discharged from the hospital
after haematological reconstitution without need for fur-
ther outpatient treatment.
All patients presented with stomatitis, though to vari-
ous degrees. Remarkably, only mild grade I stomatitis
was observed in the majority of patients (n = 17, 81%),
and as few as 2 and 2 patients developed grade II and III
stomatitis, respectively. Grade III mucositis was defined
as a reason for hospital admission.
Red cell and platelet transfusion was performed on 6
patients (29%) and 15 patients (71%) overall, respect-
ively, without significant differences found between the
two patient cohorts.
Infectious complications
Neutropenic fever was observed in 14 patients (67%). In 4
patients, prolonged neutropenic fever longer than 72 h
was a reason for hospital admission. 3 patients with neu-
tropenic fever >72 h had only low increase of temperature
and were in a good overall condition, so a hospital admis-
sion was not initiated (patient no. 2, 15, 19). All of the pa-
tients who developed neutropenic fever were treated with
i.v. antibiotics (mainly ertapenem 1 mg/d i.v.). In 4 outpa-
tients and 1 inpatient, i.v. antibiotic treatment was initi-
ated due to subfebrile temperatures and CRP elevation.
In 4 patients, the peripheral blood cultures were posi-
tive. In one patient (no. 10), Streptococcus mitis was de-
tected in peripheral blood culture. An i.v. antibiotic
therapy with ertapenem was initiated in this patient on
an outpatient basis because the criteria for hospital ad-
mission were not fulfilled. In 2 patients, peripheral blood
cultures were positive for Staphylococcus aureus (patient
no. 1) and Staphylococcus hominis (patient no. 16), re-
spectively, and a port catheter explantation was per-
formed in these patients due to a suspicion of a port
catheter infection. Moreover, Escherichia coli was de-
tected in peripheral blood cultures; in this case, inpatient
treatment was initiated (patient no. 18). In no case any
multi-resistant bacteria were detected. In one patient
(no. 7), a port catheter explantation was performed due
to persisting fever without any evidence of germs in per-
ipheral or central blood cultures. One patient developed
slight diarrhoea, and in one patient, a urinary tract infec-
tion was documented. No pulmonary infections and se-
vere adverse events (SAE) were observed. Table 3 gives
an overview of the post-ABSCT treatment, toxicities and
supportive care provided.
Hematopoietic reconstitution
The time in aplasia was 11 (range 8–15) and 9 (range 7–
11) days in out- and inpatients (P = 0.11), respectively.
The median time to reach leucocytes ≥1.0 × 109/L after
ABSCT was 15 (range 13–20) and 13 (11–16) days for
out- and inpatients, respectively. In addition, 14 (range
13–20) and 14 (12–16) days for out- and inpatients were
required to reach neutrophil recovery ≥0.5 × 109/L. No
significant differences in leucocyte and neutrophil recon-
stitution were observed between both groups (P = 0.11
and P = 0.23, respectively). A statistical comparison be-
tween the groups in terms of neutrophil recovery was
limited by a lack of available neutrophil recovery data.
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Because the majority of patients (n = 15, 71%) received a
platelet transfusion, platelet recovery ≥20 × 109/L could
not be evaluated sufficiently. The median number of days
to reach platelets ≥50 × 109/L after ABSCT was 14 (range
11–22) in outpatients and 14 (range 11–25) in temporary
inpatients. No significant differences in platelet recovery
≥50 × 109/L were observed between both patient cohorts
(P = 0.97). The hematopoietic reconstitution data after
ABSCT are summarized in Table 4. Similar results were
observed when leucocyte, neutrophil and platelet reconsti-
tution was analysed as a function of time, using both
Kaplan-Meier analysis and log-rank test for curve com-
parison. No significant differences were found with regard
to leucocytes recovery ≥1.0 × 109/L (P = 0.14), neutrophil
recovery ≥0.5 × 109/L (P = 0.33) and platelet recovery
≥50 × 109/L (P = 0.59) between the patient cohorts.
Table 1 Patients’ characteristics
Parameters Overall cohort Outpatient treatment Hospital admission P-value
Patient number, n 21 14 7 /
Gender, n (%) 0.61
Male 15 (71) 9 (64) 6 (86)
Female 6 (29) 5 (36) 1 (14)
ECOG, n (%)
0–1 21 (100) 14 (100) 7 (100) 1.00
Social conditions, n (%) besser 0.33
Accompanying person available 20 (95) 14 (100) 6 (86)
Single 1 (5) 0 (0) 1 (14)
Implanted port catheter, n (%) 0.53
yes 19 (90) 12 (86) 7 (100)
no 2 (10) 2 (14) 0 (0)
Diagnosis of MM
Age at first diagnosis, years 58 (43–67) 57 (43–67) 59 (47–66) 0.85
Stage at first diagnosis III, n (%) 1.00
A 21 (100) 14 (100) 7 (100)
B 0 (0) 0 (0) 0 (0)
Heavy chain type, n (%) 0.34
IgG 11 (52) 9 (64) 2 (29)
IgA 9 (43) 5 (36) 4 (57)
Light chain only 1 (5) 0 (0) 1 (14) 0.33
Light chain type, n (%) 1.00
κ 13 (62) 9 (64) 4 (57)
λ 8 (38) 5 (36) 3 (43)
Induction therapy, n (%) 0.61
PAD 10 (48) 5 (36) 5 (71)
VAD 2 (10) 2 (14) 0 (0)
VCD 8 (38) 6 (43) 2 (29)
Other 1 (5) 1 (7) 0 (0)
Mobilization therapy, n (%) 1.00
1xCAD 20 (95) 13 (93) 7 (100)
Other 1 (5) 1 (7) 0 (0)
PBSC collection
Age at PBSC collection, years 59 (44–67) 57 (44–67) 59 (47–67) 0.79
Collected CD34+ cells × 106/kg 11.8 (7.4–24.8) 9.7 (7.4–24.8) 13.7 (9.1–23.0) 0.20
CAD cyclophosphamide, doxorubicin, dexamethasone, ECOG Eastern Cooperative Oncology Group, MM multiple myeloma, PAD bortezomib, doxorubicin,
dexamethasone, PBSC peripheral blood stem cells, VAD vincristine, doxorubicin, dexamethasone, VCD bortezomib, cyclophosphamide, dexamethasone. Unless
otherwise indicated, data are given as medians (range)
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Patients’ satisfaction
According to the ratings given by the patients in the
questionnaire, the level of satisfaction was high: on a
scale from 1 (excellent) to 6 (insufficient), physicians got
a rating of 1.1, nurses of 1.2 and the treatment as a
whole got a rating of 1.3 (mean values, n = 20). All of the
patients agreed, if indicated, to undergo further HD
chemotherapy and ABSCT in an outpatient setting
again. In 3 cases, patients had indeed two consecutive
autologous transplants within the program (#6/#18, #8/
#10 and #9/#12).
Discussion
In Europe, HD melphalan chemotherapy followed by
ABSCT is performed almost always on an inpatient
basis, and only scattered reports on outpatient HD
chemotherapy exist [23]. In contrast, in the USA and
Canada, outpatient HD chemotherapy and ABSCT in
MM and lymphoma patients has been well established
for decades [19] and is performed with a high degree of
safety [16–18, 26], cost savings [14, 15, 20] and patient
satisfaction [13]. As one of the first centres in Europe,
we established an outpatient ABSCT program at our in-
stitution in 2012. Based on our inpatient HD melphalan
chemotherapy and ABSCT treatment protocol, we devel-
oped a comprehensive treatment plan for an outpatient
setting. Patients were carefully selected and criteria have
been developed for hospital admission. Comprehensive
patient education about how to behave during aplasia at
home took place. Moreover, daily rounds of the outpa-
tients, including vital parameter monitoring, and labora-
tory tests were performed. The outpatient ABSCT
program also included the advanced management of side
effects exceeding the standard inpatient care, including a
triple anti-emetic regimen, strong recommendation to
rinse the mouth with Caphosol® at least once an hour and
administration of daily i.v. fluids. Furthermore, with regard
to Kim et al., who showed that sequential prophylaxis with
oral fluoroquinolone followed by i.v. ertapenem may
effectively prevent episodes of bacteremia and hospitaliza-
tions in neutropenic MM outpatient ABSCT recipients
[27], an empirical i.v. antibiotic therapy was initiated at
subfebrile body temperatures when CRP elevation was
detected.
Between 2012 and 2016, 21 MM patients underwent
HD chemotherapy and ABSCT on an outpatient basis.
Table 2 HD chemotherapy and transplant characteristics
Parameters Overall cohort
ABSCT number, n 21
Age at ABSCT, years 59 (51–70)
Therapy line, n (%)
First line therapy 15 (71)
Salvage therapy 6 (29)









HD melphalan n, (%) 20 (95)
Dose modification, n (%) 1 (5)
ABSCT
Transplanted CD34+ cells × 106/kg 3.3 (2.1–6.5)
PBSC storage duration, months 2 (0–144)








ABSCTautologous blood stem cell transplantation, (n)CR (near) complete remission,
HD high dose, MR minimal response, PBSC peripheral blood stem cells, PD
progressive disease, PR partial remission, SD stable disease, VGPR very
good partial remission. Unless otherwise indicated, data are given as
medians (range)
Fig. 1 Out- and inpatient stay. Days as out- and inpatient are
indicated for each patient. The numerical sequence of the patients
(patient number 1 to 21) corresponds to the chronology of the
performed ABSCTs
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No SAEs were observed. In our patient cohort, con-
firmed post-transplant infections were documented in 5
of the 21 patients (24%, positive blood cultures in 4 pa-
tients and 1 positive urine culture in 1 patient). This is
comparable to the results of Paul et al., who reported an
infection rate of 22% (18 of 82 patients) in an initial brief
in-hospital stay of MM patients group receiving HD
melphalan and ABSCT [17], and to Graff et al., who de-
scribed an infection rate of 19% (19 of 95 patients) in
MM and lymphoma patients undergoing this therapy as
outpatients [18]. Less than 10% of patients (2 of 21) de-
veloped grade 3 stomatitis. No grade 4 or 5 stomatitis
cases were observed. In contrast, Jagannath et al. re-
ported a stomatitis grade ≥3 in 31% of 118 MM patients
Table 3 Post-ABSCT treatment, toxicities and supportive care
Parameters Overall cohort Outpatient treatment Hospital admission P-value
ABSCT number, n 21 14 7 /
Treatment duration
Overall, days 21 (18–31) 21 (18–25) 22 (19–31) 0.38
Days as outpatient 19 (8–25) 21 (18–25) 15 (8–19) <0.01
Days as inpatient 0 (0–18) / 5 (2–18) <0.01
Reason for hospital admission, n (%) /
Neutropenic fever ≥72 h 4 (19) / 4 (57)
Grade III stomatitis 2 (10) / 2 (29)
Other 1 (5) / 1 (14)
Toxicities
Stomatitis, n (%)
I 17 (81) 13 (93) 4 (57)
II 2 (10) 1 (7) 1 (14)
III 2 (10) 0 (0) 2 (29)
Neutropenic fever
n, (%) 14 (67) 8 (57) 6 (86) 0.34
No. of days with fever 3 (1–10) 2 (1–7) 4 (2–10) 0.14
Diarrhoea, n (%) 1 (5) 1 (7) 0 (0) 1.00
Pulmonary infection, n (%) 0 (0) 0 (0) 0 (0) 1.00
Urinary tract infection, n (%) 1 (5) 0 (0) 1 (14) 0.33
Positive blood cultures, n (%)
Peripheral 4 (19) 1 (7) 3 (43) 0.09
Central 0 (0) 0 (0) 0 (0) 1.00
Port catheter infection, n (%)
Suspicion of 3 (14) 0 (0) 3 (43) 0.03
Proven 0 (0) 0 (0) 0 (0) 1.00
Port catheter explantation 3 (14) 0 (0) 3 (43) 0.03
SAE, n (%) 0 (0) 0 (0) 0 (0) 1.00
Support/Intervention
Red cell transfusion, n (%) 6 (29) 3 (21) 3 (43) 0.35
Platelet transfusion, n (%) 15 (71) 9 (64) 6 (86) 0.61
i.v. antibiotics
In case of neutropenic fever, n (%) 14 (67) 8 (57) 6 (86) 0.34
At subfebrile temperature, n (%) 5 (24) 4 (29) 1 (14) 0.62
Overall, days 7 (4–14) 7 (4–10) 8 (4–14) 0.61
Days as outpatient 6 (1–10) 7 (4–10) 1 (0–6) /
Days as inpatient 5 (2–14) / 5 (2–14) /
ABSCT autologous blood stem cell transplantation, i.v. intravenous, no. number, SAE severe adverse event. Unless otherwise indicated, data are given as medians (range)
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undergoing outpatient HD chemotherapy and ABSCT
[15]. We attribute the low mucositis rate in our patient
cohort to regular Caphosol® mouth rinse. Neutropenic
fever was observed in two-thirds of the cases. However,
the median fever duration was relatively short (2 and
4 days for outpatients and those who required a hospital
admission, respectively), and the majority of patients
with neutropenic fever (8 of 14) were not admitted for
inpatient stay. The neutropenic fever rate is comparable
to those observed by Jagannath et al. (50% of 118 out-
patient MM auto-transplants [15]) and Leger et al. (56%
of 60 outpatient ABSCTs in relapse follicular lymphoma
[21]). Moreover, the observed neutropenic fever rate was
relatively low compared to in-house historical patient
cohorts undergoing HD chemotherapy and ABSCT, with
rates of approximately 80% [28, 29]. Although Meisen-
berg et al. and Paul et al. reported a pulmonary infection
rate of 4% (of 27 patients [16]) and 5% (of 82 MM
patients [17]) in outpatient auto-transplantation cases,
respectively, no pulmonary infections were documented
in our patient cohort.
The rate of positive blood cultures in our patient co-
hort (19%, 4 of 21 patients) is in line with the observa-
tion of Graff et al. (10%, 9 of 95 MM and lymphoma
ABSCT receiving outpatients [18]) and Paul et al. (16%, 13
of 82 MM patients with an initial in-hospital stay post
ABSCT [17]). Moreover, Graff et al. reported 1 central
venous line infection among 95 MM/lymphoma patients
treated on an outpatient basis (4%) [18]. In our patient
group, port explantation was performed in 3 cases (14%)
due to a clinical suspicion of port infection upon persist-
ing fever, but without definitive prove of infection by bac-
terial culture. 90% (19 of 21) of transplanted patients
received i.v. antibiotics. Compared to Jagannath et al. who
reported a use of i.v. antibiotics in 78% (of 118 MM
patients) transplanted in an outpatient setting [15] the
higher relative number of patients with i.v. antibiotics in
our group can be attributed to an early intervention
strategy with initiation of ertapenem infusion at subfebrile
temperatures and elevated CRP levels.
Graff et al. observed a neutrophil ≥0.5 × 109/L recovery
and platelet ≥20 × 109/L after a median of 10 and
19 days, respectively, in a cohort of MM and lymphoma
patients undergoing outpatient ABSCT. We observed
neutrophil ≥0.5 × 109/L recovery and platelet recovery
after a median of 14 days in both groups, which is al-
most identical with study data of two historical in-house
patient cohorts undergoing HD chemotherapy and
ASCT at our institution, with the time to leukocyte in-
crease ≥1 × 109/L and time to platelet increase ≥50 ×
109/L being a median of 14 days [28, 29]. Pack red cell
and platelet transfusion was necessary in 6 (29%) and 15
(71%) patients. This corresponds to the findings of
Jagannath et al. (57% and 97%) [15].
On average, the median treatment duration was 21
and 22 days for outpatients and those who were inter-
mittently admitted to the hospital, respectively. This is
in line with the treatment duration of a completely in-
hospital-treated MM patient undergoing HD chemother-
apy and ABSCT at our institution [29]. Hospital admis-
sion was indicated in one-third (7 of 21) of the auto-
transplanted MM patients in our cohort. In a compar-
able MM patient group described by Jagannath et al.,
21% of the 118 outpatient transplant procedures re-
quired hospital admission [15]. However, in a cohort of
82 MM patients who had an initial brief hospital stay
and were followed as outpatients, as described by Paul et
al., 67% required hospital re-admission [17]. In our MM
patient group, patients who were admitted to the hos-
pital had a relatively short median inpatient treatment of
5 days, and the necessity of hospital admission did not
lead to prolonged overall treatment duration. Thus, the
temporary inpatient treatment-duration in our cohort
was even shorter compared to the cohort of outpatient
ABSCTs performed in patients with different
hematologic malignancies reported by McDiarmid et al.
Table 4 Hematopoietic reconstitution
Parameters Overall cohort Outpatient treatment Hospital admission P-value
Days to L <1.0 × 109/L 4 (2–5) 4 (3–5) 4 (2–5) 0.83
Days to L ≥1.0 × 109/L 14 (11–20) 15 (13–20) 13 (11–16) 0.11
Days in aplasia 10 (7–15) 11 (8–15) 9 (7–11) 0.11
Days to N ≥0.5 × 109/L 14 (12–20) 14 (13–20) 14 (12–16) 0.23
Platelets ≥20 × 109/L
Platelet transfusion, n (%) 15 (71) 9 (64) 6 (86) 0.61
Analysed ABSCTs, n (%) 6 (29) 5 (36) 1 (14) /
Days to platelets ≥20 × 109/L 10 (9–16) 10 (9–11) 16 /
Platelets ≥50 × 109/L
Days to platelets ≥50 × 109/L 14 (11–25) 14 (11–22) 14 (11–25) 0.97
ABSCT autologous blood stem cell transplantation, L leucocytes, NA not available, N neutrophils. Unless otherwise indicated, data are given as medians (range)
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(median total length of stay 21 d, median inpatient 7 d
and median outpatient 14 d) [30].
Overall, approximately 90% (391 days) of the overall
cumulative treatment days for 21 patients were spent on
an outpatient basis and 10% (53 days) on an inpatient
basis. With increasing numbers of outpatient ABSCTs at
our centre, the relatively short inpatient stay will repre-
sent a significant cost saving option. The magnitude of
this effect depends on a number of factors, including
reimbursement for in-/outpatient ABSCT, occupancy
rate of hospital beds, staff availability etc., and should be
addressed in detail in future studies.
Limitations of the presented data result from the rela-
tively small number of outpatients. In addition, this
patient cohort was carefully selected and represented
only about 5% of all transplanted myeloma-patients at
our center during that time period. It therefore repre-
sents a pilot-study aiming to proof the feasibility and to
describe the necessary preconditions.
According to the results of the structured question-
naire, the patient’s satisfaction with outpatient medical
care provided by physicians and nurses as well as their
treatment in the outpatient clinic as a whole was very
high. In addition, all of the patients indicated willingness
to undergo further HD chemotherapy and ABSCT
within the outpatient program again, if indicated. This
was actually the case in three patients. Further continu-
ation and expansion of the program is intended.
Conclusions
Carefully selected MM patients undergoing HD chemo-
therapy and ABSCT can successfully be treated on an
outpatient basis with low morbidity and infectious compli-
cations and very high patient satisfaction. Although
dependent on a number of variables, including the indi-
vidual compensation agreement with the health-insurance
providers, such an approach may also have a significant
economic impact on the performing transplant centre.
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